These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11327200)

  • 21. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
    Larsson G; Hallén B; Nilvebrant L
    Urology; 1999 May; 53(5):990-8. PubMed ID: 10223495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder.
    Marencak J; Cossons NH; Darekar A; Mills IW
    Neurourol Urodyn; 2011 Jan; 30(1):75-82. PubMed ID: 20886571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers.
    Rahimy M; Hallén B; Narang P
    Arzneimittelforschung; 2002; 52(12):890-5. PubMed ID: 12572529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
    Swift S; Garely A; Dimpfl T; Payne C;
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.
    Abrams P
    Expert Opin Pharmacother; 2001 Oct; 2(10):1685-701. PubMed ID: 11825311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
    Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
    Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).
    Siami P; Seidman LS; Lama D
    Clin Ther; 2002 Apr; 24(4):616-28. PubMed ID: 12017406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
    Brynne N; Böttiger Y; Hallén B; Bertilsson L
    Br J Clin Pharmacol; 1999 Feb; 47(2):145-50. PubMed ID: 10190648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolterodine extended release is well tolerated in older subjects.
    Griebling TL; Kraus SR; Richter HE; Glasser DB; Carlsson M
    Int J Clin Pract; 2009 Aug; 63(8):1198-204. PubMed ID: 19624787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.
    Brynne N; Stahl MM; Hallén B; Edlund PO; Palmér L; Höglund P; Gabrielsson J
    Int J Clin Pharmacol Ther; 1997 Jul; 35(7):287-95. PubMed ID: 9247842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
    Shin D; Shin KH; Lee S; Lim KS; Cho JY; Jang IJ; Shin SG; Yu KS
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):722-8. PubMed ID: 22853865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The overactive bladder in children: a potential future indication for tolterodine.
    Hjälmås K; Hellström AL; Mogren K; Läckgren G; Stenberg A
    BJU Int; 2001 Apr; 87(6):569-74. PubMed ID: 11298060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A formulation approach for development of HPMC-based sustained release tablets for tolterodine tartrate with a low release variation.
    Cao QR; Choi JS; Liu Y; Xu WJ; Yang M; Lee BJ; Cui JH
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1720-30. PubMed ID: 23062115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.
    Hua TC; Pan A; Chan C; Poo YK; Skinner MH; Knadler MP; Gonzales CR; Wise SD
    Br J Clin Pharmacol; 2004 May; 57(5):652-6. PubMed ID: 15089819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation and evaluation of once-daily sustained-release coated tablets of tolterodine-L-tartrate.
    Pradhan R; Kim YI; Chang SW; Kim JO
    Int J Pharm; 2014 Jan; 460(1-2):205-11. PubMed ID: 24184032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.